Table 4.
Sex/Age y | Comorbidities | Concomitant treatment | SK1 | SNa1 | SC2 | GFR3 | HCO31 | SK/UK ratio | FEK | UK/UC ratio | UNa1 | UK1 | UNa/uK ratio | Uosm4 | TTKG | Cortisol5 | PAC6 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case 1 | F/68 | HTA, PDH | ACEI/ARB | 4.2 | 130 | 0.77 | 150 | NM | 0.14 | 9.5 | 51.9 | 81 | 31 | 2.61 | 490 | 4.2 | 14.8 | 88 |
Case 2 | F/83 | HTA, PDH, MN | Hep, ACEI/ARB, TD | 3.6 | 118 | 0.46 | 186 | NM | 0.11 | NM | NM | 60 | 32 | 1.88 | 527 | 4.4 | 29 | 7 |
Case 3 | F/89 | DM, HTA, LSI | ACEI/ARB, LD | 4.4 | 134 | 1.17 | 103 | NM | 0.23 | 11.2 | 42.1 | 60 | 19 | 3.16 | 285 | 4.3 | 15.9 | NM |
Case 4 | M/78 | HTA, PDH, LSI | ACEI/ARB | 4.6 | 126 | 1.36 | 86 | NM | 0.18 | NM | NM | 68 | 25 | 2.72 | 294 | 5 | 16.3 | 218 |
Case 5 | F/90 | DM, HTA, MN, LSI | CG, βB, ACEI/ARB, LD | 4.2 | 124 | 0.97 | 129 | NM | 0.10 | NM | NM | 36 | 41 | 0.88 | 514 | 5.3 | NM | NM |
Case 6 | F/90 | HTA, CKD, RT, MN, LSI | ACEI/ARB | 4.3 | 127 | 1.17 | 75 | 22.3 | 0.19 | 4.8 | 17.6 | 36 | 23 | 1.57 | 312 | 4.6 | 21 | 83 |
F, female; M, male; HTA, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; RT, renal transplantation; PDH, prior dilutional hyponatremia; MN, malnutrition; low-salt intake; ACEI/ARB, angiotensin-converting enzyme inhibitors or angiotensin-2 receptor blockers; Hep, heparin; TD, thiazide; LD, loop diuretics; CG, chronic glucocorticoid therapy ≥ 6 weeks; βB, beta-blockers; NM, no measured. SK, serum potassium mmol/L; SNa, serum sodium; SC, serum creatinine; GFR, glomerular filtrate rate; HCO3, blood bicarbonate; FEK, fractional excretion of K; UK, urine potassium; UC, urine creatinine; UNa, urinary sodium; Uosm, urine osmolality; TTKG, transtubular potassium gradient.
1mmol/L, 2mg/dL, 3ml/min/1.73m2, 4mOsm/kg, 5µg/dL, 6pg/mL.